-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Selvigaltin in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Selvigaltin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Selvigaltin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drug Details: Selvigaltin...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Selvigaltin in Decompensated Cirrhosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Selvigaltin in Decompensated Cirrhosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Selvigaltin in Decompensated Cirrhosis Drug Details: Selvigaltin is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GB-1211 in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. GB-1211 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drug Details: GB-1211 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GB-1211 in Decompensated Cirrhosis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. GB-1211 in Decompensated Cirrhosis Drug Details: GB-1211 is under development for the treatment of liver cirrhosis,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lifirafenib Maleate in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lifirafenib Maleate in Ovarian Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lifirafenib Maleate in Ovarian Cancer Drug Details: Lifirafenib maleate is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GB-2064 in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GB-2064 in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.GB-2064 in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) Drug Details:GB-2064 (PAT-1251)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GB-2064 in Post-Polycythemia Vera Myelofibrosis (PPV-MF)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GB-2064 in Post-Polycythemia Vera Myelofibrosis (PPV-MF) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.GB-2064 in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Drug Details:GB-2064 (PAT-1251) Is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tagtociclib in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tagtociclib in Metastatic Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tagtociclib in Metastatic Breast Cancer Drug Details: Tagtociclib (PF-07104091) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GB-1211 in Liver Cirrhosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GB-1211 in Liver Cirrhosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GB-1211 in Liver Cirrhosis Drug Details: GB-1211 is under development for the...